MA26427A1 - Trihydrate de mesylate de 5-(2-(4-(1,2-benzisothiazole-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indole-2-one, procede pour sa preparation et compositions pharmaceutiques le contenant - Google Patents
Trihydrate de mesylate de 5-(2-(4-(1,2-benzisothiazole-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indole-2-one, procede pour sa preparation et compositions pharmaceutiques le contenantInfo
- Publication number
- MA26427A1 MA26427A1 MA24594A MA24594A MA26427A1 MA 26427 A1 MA26427 A1 MA 26427A1 MA 24594 A MA24594 A MA 24594A MA 24594 A MA24594 A MA 24594A MA 26427 A1 MA26427 A1 MA 26427A1
- Authority
- MA
- Morocco
- Prior art keywords
- benzisothiazole
- piperazinyl
- indole
- dihydro
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1653796P | 1996-05-07 | 1996-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA26427A1 true MA26427A1 (fr) | 2004-12-20 |
Family
ID=21777622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA24594A MA26427A1 (fr) | 1996-05-07 | 1997-05-06 | Trihydrate de mesylate de 5-(2-(4-(1,2-benzisothiazole-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indole-2-one, procede pour sa preparation et compositions pharmaceutiques le contenant |
Country Status (45)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| UA57734C2 (uk) | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
| TW491847B (en) | 1996-05-07 | 2002-06-21 | Pfizer | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| DE69910706T2 (de) * | 1998-05-26 | 2004-07-08 | Pfizer Products Inc., Groton | Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie |
| US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
| IL149186A0 (en) | 1999-12-23 | 2002-11-10 | Pfizer Prod Inc | Pharmaceutical compositions providing enhanced drug concentrations |
| CN1431901A (zh) * | 2000-06-02 | 2003-07-23 | 辉瑞产品公司 | 用于治疗精神病和眼科疾病的s－甲基－二氢一齐拉昔酮 |
| AR032641A1 (es) * | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| US8703772B2 (en) | 2001-09-25 | 2014-04-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US20040048876A1 (en) * | 2002-02-20 | 2004-03-11 | Pfizer Inc. | Ziprasidone composition and synthetic controls |
| UY27668A1 (es) * | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | Composición de ziprasidona y controles sintéticos |
| AU2003300814A1 (en) | 2002-12-04 | 2004-06-23 | Dr. Reddy's Laboratories Inc. | Polymorphic forms of ziprasidone and its hydrochloride |
| WO2004050655A1 (en) * | 2002-12-04 | 2004-06-17 | Dr. Reddy's Laboratories Limited | Polymorphic forms of ziprasidone and its hydrochloride |
| MXPA05012325A (es) * | 2003-05-16 | 2006-01-30 | Pfizer Prod Inc | Procedimiento para potenciar la cognicion usando zipirasidona. |
| MXPA05012392A (es) * | 2003-05-16 | 2006-02-02 | Pfizer Prod Inc | Tratamientos de ansiedad con ziprasidona. |
| CA2525866A1 (en) * | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Treatment of psychotic and depressive disorders |
| EP1546146A1 (en) * | 2003-06-03 | 2005-06-29 | Teva Pharmaceutical Industries Limited | POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION |
| CA2537413A1 (en) * | 2003-09-02 | 2005-03-10 | Imran Ahmed | Sustained release dosage forms of ziprasidone |
| CA2543805A1 (en) * | 2003-10-24 | 2005-05-06 | Gideon Pilarsky | Processes for preparation of ziprasidone |
| EP1592688A2 (en) * | 2003-12-18 | 2005-11-09 | Teva Pharmaceutical Industries Ltd. | Polymorphic form b2 of ziprasidone base |
| CA2552126A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Ziprasidone formulations |
| PT1720867E (pt) * | 2004-02-27 | 2010-01-28 | Ranbaxy Lab Ltd | Processo para a preparação de ziprasidona |
| WO2006026426A2 (en) * | 2004-08-27 | 2006-03-09 | University Of Kentucky Research Foundation | Amyloid peptide inactivating enzyme to treat alzheimer’s disease peripherally |
| ES2250001B1 (es) * | 2004-09-29 | 2007-06-01 | Medichem, S.A. | Proceso para la purificacion de ziprasidona. |
| US7777037B2 (en) * | 2004-10-27 | 2010-08-17 | Dr. Reddy's Laboratories Limited | Ziprasidone process |
| CA2587710C (en) * | 2004-11-16 | 2014-10-21 | Elan Pharma International Ltd. | Injectable nanoparticulate olanzapine formulations |
| EP1863806A1 (en) * | 2005-02-11 | 2007-12-12 | Teva Pharmaceutical Industries Ltd | Amorphous ziprasidone mesylate |
| CA2598288A1 (en) * | 2005-03-03 | 2006-09-14 | Elan Pharma International Limited | Nanoparticulate compositions of heterocyclic amide derivatives |
| ITMI20050346A1 (it) | 2005-03-07 | 2006-09-08 | Dipharma Spa | Forma solida di ziprasidone cloridrato |
| EP1858892A1 (en) * | 2005-03-14 | 2007-11-28 | Teva Pharmaceutical Industries Ltd | Anhydrous ziprasidone mesylate and a process for its preparation |
| US20060270684A1 (en) * | 2005-03-14 | 2006-11-30 | Judith Aronhime | Crystalline forms of ziprasidone mesylate |
| JP2010527925A (ja) * | 2007-05-18 | 2010-08-19 | サイドース・エルエルシー | ジプラシドン製剤 |
| KR100948126B1 (ko) * | 2007-12-10 | 2010-03-18 | 씨제이제일제당 (주) | 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물 |
| CN102234273B (zh) * | 2010-04-21 | 2015-08-05 | 上海医药工业研究院 | 甲磺酸齐拉西酮半水合物及其制备方法 |
| SI23610A (sl) | 2011-01-13 | 2012-07-31 | Diagen@d@o@o | Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji |
| CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
| US5359068A (en) * | 1993-06-28 | 1994-10-25 | Pfizer Inc. | Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one |
-
1997
- 1997-03-26 CN CN97194243A patent/CN1092658C/zh not_active Expired - Lifetime
- 1997-03-26 HU HU9902808A patent/HU229057B1/hu unknown
- 1997-03-26 EA EA199800909A patent/EA001180B1/ru not_active IP Right Cessation
- 1997-03-26 UA UA98105559A patent/UA47467C2/uk unknown
- 1997-03-26 PT PT97907237T patent/PT904273E/pt unknown
- 1997-03-26 BR BR9708932A patent/BR9708932A/pt not_active IP Right Cessation
- 1997-03-26 NZ NZ508303A patent/NZ508303A/en not_active IP Right Cessation
- 1997-03-26 WO PCT/IB1997/000306 patent/WO1997042190A1/en active IP Right Grant
- 1997-03-26 TR TR1998/02241T patent/TR199802241T2/xx unknown
- 1997-03-26 EP EP97907237A patent/EP0904273B1/en not_active Expired - Lifetime
- 1997-03-26 SI SI9730526T patent/SI0904273T1/xx unknown
- 1997-03-26 IL IL12659097A patent/IL126590A/en not_active IP Right Cessation
- 1997-03-26 PL PL97329880A patent/PL188164B1/pl unknown
- 1997-03-26 AU AU19368/97A patent/AU730856C/en not_active Expired
- 1997-03-26 KR KR1019980708958A patent/KR100333214B1/ko not_active Expired - Lifetime
- 1997-03-26 DK DK97907237T patent/DK0904273T3/da active
- 1997-03-26 CA CA002252895A patent/CA2252895C/en not_active Expired - Lifetime
- 1997-03-26 JP JP09539668A patent/JP3102896B2/ja not_active Expired - Lifetime
- 1997-03-26 ES ES97907237T patent/ES2192264T3/es not_active Expired - Lifetime
- 1997-03-26 SK SK1505-98A patent/SK282674B6/sk not_active IP Right Cessation
- 1997-03-26 AT AT97907237T patent/ATE236902T1/de active
- 1997-03-26 US US09/180,456 patent/US6110918A/en not_active Expired - Lifetime
- 1997-03-26 CZ CZ19983494A patent/CZ289216B6/cs not_active IP Right Cessation
- 1997-03-26 NZ NZ332219A patent/NZ332219A/en not_active IP Right Cessation
- 1997-03-26 DE DE69720719T patent/DE69720719T2/de not_active Expired - Lifetime
- 1997-04-01 TW TW086104175A patent/TW427989B/zh not_active IP Right Cessation
- 1997-04-02 HN HN1997000040A patent/HN1997000040A/es unknown
- 1997-04-10 GT GT199700042A patent/GT199700042A/es unknown
- 1997-04-28 CO CO97022512A patent/CO4940465A1/es unknown
- 1997-04-30 AP APAP/P/1997/000978A patent/AP838A/en active
- 1997-05-04 EG EG37797A patent/EG24401A/xx active
- 1997-05-05 AR ARP970101855A patent/AR007003A1/es unknown
- 1997-05-05 ID IDP971490A patent/ID17504A/id unknown
- 1997-05-06 DZ DZ970068A patent/DZ2221A1/fr active
- 1997-05-06 ZA ZA973875A patent/ZA973875B/xx unknown
- 1997-05-06 ME MEP-1997-173A patent/ME00901B/me unknown
- 1997-05-06 MY MYPI97001988A patent/MY128051A/en unknown
- 1997-05-06 UY UY24543A patent/UY24543A1/es not_active IP Right Cessation
- 1997-05-06 MA MA24594A patent/MA26427A1/fr unknown
- 1997-05-06 YU YU17397A patent/YU49398B/sh unknown
- 1997-05-06 TN TNTNSN97073A patent/TNSN97073A1/fr unknown
- 1997-05-07 HR HR970235A patent/HRP970235B1/xx not_active IP Right Cessation
-
1998
- 1998-10-23 IS IS4878A patent/IS2301B/is unknown
- 1998-10-30 OA OA9800205A patent/OA10908A/fr unknown
- 1998-11-03 BG BG102893A patent/BG63601B1/bg unknown
- 1998-11-06 NO NO19985193A patent/NO312513B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA26427A1 (fr) | Trihydrate de mesylate de 5-(2-(4-(1,2-benzisothiazole-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indole-2-one, procede pour sa preparation et compositions pharmaceutiques le contenant | |
| MA26432A1 (fr) | Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26430A1 (fr) | 4 (3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26687A1 (fr) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| FR2780728B1 (fr) | Sel de paroxetine nouveau, procede pour sa preparation et compositions pharmaceutiques le contenant | |
| MA26598A1 (fr) | 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur préparation et compositions pharmaceutiques les contenant | |
| MA26438A1 (fr) | Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| FR2740136B1 (fr) | Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant | |
| MA26526A1 (fr) | Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| FR2780057B1 (fr) | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| RU93043528A (ru) | Моногидрат 5-(2-(4-(1,2-бензотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-он хлоргидрата, способ его получения, фармацевтическая композиция, способ лечения | |
| MA26630A1 (fr) | 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA23899A1 (fr) | Procede pour la preparation de derives de pyrimidinedione et -trione, triazinedione et quinazolinedione, procede de preparation de compositions pharmaceutiques les contenant et leur utilisation | |
| MA26559A1 (fr) | Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation | |
| MA26536A1 (fr) | Association de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation. | |
| MA26468A1 (fr) | Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26443A1 (fr) | Aralkyl- et aralkylidene-lactames et -imides heterocycliques, procedes pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26519A1 (fr) | Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| CA2252898A1 (en) | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one(=ziprasidone), its preparation and its use as dopamine d2 antagonist | |
| MA26523A1 (fr) | Modification thermodynamiquement stable de 1-(4-carbazolyloxy)-3-(2-(2-methoxyphenoxy) ethylamino)-2-propanole, procede pour sa preparation et compositions pharmaceutiques le comprenant | |
| MA26417A1 (fr) | Azetidines, procede pour leur preparation, et compositions pharmaceutiques les contenant | |
| MA26582A1 (fr) | Derives de thiazolidinedione nouveau, procede pour sa preparation et composition pharmaceutique le contenant | |
| FR2728901B1 (fr) | Derives de phenyl-4-thiazoles substitues, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26708A1 (fr) | Derive d'indole nouveau, procede pour sa preparation et compositions pharmaceutiques le contenant | |
| HUP9901212A3 (en) | N-[2-(3-alkoxy-phenoxy)-ethyl]-dialkylamine derivatives, pharmaceutical compositions containing the same and their use as local anaesthetics |